Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate development of its novel PH1 payload, an RNA splicing modulating antibody drug conjugate (ADC) currently being developed for metastatic urothelial cancer. The collaboration aims to fast-track the first-in-human clinical trial of Akari's lead candidate AKTX-101, leverag…